Search clinical trials for: SY-1425 (tamibarotene)

Total 627 results

Syros Pharmaceuticals

Recruiting

Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States, Spain, Belgium, Israel, France, United Kingdom, Austria, Czechia, Italy, Poland, Canada, Hungary, Germany
Syros Pharmaceuticals

Completed

A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States, France
St. Marianna University School of Medicine

Unknown

Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)

HTLV-I-Associated Myelopathy

Japan
R&R Inc.

Completed

Phase II Study of RR110 in Patients With Active Crohn's Disease

Crohn's Disease

Japan
Osaka City University

Unknown

Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease

Alzheimer's Disease

Japan
Shouyao Holdings (Beijing) Co. LTD

Recruiting

Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC

Non-Small Cell Lung Cancer

China
Shouyao Holdings (Beijing) Co. LTD

Recruiting

Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor

Non-Small Cell Lung Cancer | Solid Tumor | Medullary Thyroid Cancer

China
Shouyao Holdings (Beijing) Co. LTD

Recruiting

A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation

Advanced Solid Tumor

China
Shouyao Holdings (Beijing) Co. LTD

Recruiting

A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Shouyao Holdings (Beijing) Co. LTD

Recruiting

A Phase I Study of SY-4835 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Suspended

SY007 in Patients With Acute Ischemic Stroke

Acute Ischemic Stroke

China
Kinki University

Unknown

Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis

Lupus Nephritis

Japan
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Multiple Ascending Doses of SY-009 in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Multiple Ascending Doses of SY-008 in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Rege Nephro Co., Ltd.

Recruiting

Study of Tamibarotene in Patients With ADPKD

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Japan
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single Ascending Oral Doses of SY-009 in Healthy Subjects

Diabetes

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single Ascending Oral Doses of SY-008 in Healthy Subjects

Diabetes

China
Shouyao Holdings (Beijing) Co. LTD

Not yet recruiting

A Study to Evaluate the Food Effects on Pharmacokinetics of SY-5007 Tablets in Healthy Subjects

Health Subjects

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single-dose Incremental Intravenous Injection of SY-007 in Healthy Subjects

Cerebral Apoplexy

China
Seinda Pharmaceutical Guangzhou Corporation

Completed

Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Disease

United States
CytRx

Completed

Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL (STAR-1)

Acute Promyelocytic Leukemia

United States
Shouyao Holdings (Beijing) Co. LTD

Not yet recruiting

A Study to Evaluate the Mass Balance of [14C] SY-5007 in Healthy Adult Male Subjects in China

Healthy Subjects

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Not yet recruiting

The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes

China
Shouyao Holdings (Beijing) Co. LTD

Recruiting

Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single-dose/Multiple-doses Incremental Intravenous Injection of SY-005 （Recombinant Human Annexin A5）in Healthy Subjects

Sepsis

China
CytRx

Terminated

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Stage IV Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer With Pleural Effusion

United States, Mexico, India, Ukraine, Bulgaria, Russian Federation
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Recruiting

SY-005 （Recombinant Human Annexin A5）in Patients With Sepsis

Sepsis

China
Syros Pharmaceuticals

Terminated

A Study of SY-1365 in Adult Patients With Advanced Solid Tumors

Breast Cancer | Ovarian Cancer | Advanced Solid Tumors

United States, Canada, France
Universitaire Ziekenhuizen KU Leuven

Completed

Study of Pain, Anxiety and Complications Related to Cannulation of Arteriovenous (AV) Fistula in Chronic Hemodialysis Patients

Fistula | Dialysis

Belgium
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

A Food-drug Interaction Study of SY-004 in Healthy Subjects

Type 2 Diabetes

China
Northwestern University
CytRx; Cephalon

Terminated

Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia

United States
Shouyao Holdings (Beijing) Co. LTD

Recruiting

Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI

Non-small-cell Lung Carcinoma

China
Drexel University

Unknown

Access Protocol for MAB-425 Radiolabeled With I-125 for High Grade Gliomas

Glioblastoma Multiforme | Astrocytoma Anaplastic Foci
Shouyao Holdings (Beijing) Co. LTD

Recruiting

A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors

Advanced Solid Tumor

China
M.D. Anderson Cancer Center

Active, not recruiting

iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

Pancreatic Ductal Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | KRAS NP_004976.2:p.G12D

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Transformed Non-Hodgkin Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); ADC Therapeutics S.A.

Recruiting

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Blasts 5 Percent or More of Bone Marrow Nucleated Cells | CD22 Positive

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States, Canada
Yabao Pharmaceutical Group

Completed

Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus | Hyperglycaemia (Diabetic)

China
Pulmotect, Inc.
United States Department of Defense

Completed

The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2

COVID-19

United States
Yabao Pharmaceutical Group

Completed

The Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride

Healthy Volunteers | Hyperglycaemia (Diabetic)

China
Aquinox Pharmaceuticals (Canada) Inc.
Quotient Clinical

Completed

Phase 1 Absorption Distribution Metabolism and Excretion of AQX-1125 (ADME)

Healthy Volunteer

United Kingdom
Syros Pharmaceuticals

Recruiting

Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML

Acute Myeloid Leukemia

United States, France
Lawson Health Research Institute
London Health Sciences Foundation; Ontario Ministry of Colleges and Universities

Recruiting

Annexin A5 in Patients With Severe COVID-19 Disease (AX-COVID)

Coronavirus Infection | Sepsis

Canada
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

A Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus

Uremic Pruritus in Hemodialysis Patients

Japan
University of Oklahoma

Recruiting

Pilot Window of Opportunity Trial (POET)

Colorectal Carcinoma (CRC) | Endometrial Carcinoma (EC)

United States
Bristol-Myers Squibb
Cardioxyl Pharmaceuticals, Inc

Completed

A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers

Heart Failure
Unither Pharmaceuticals, France
Raptim Research

Completed

Pharmacokinetic Study of Paracetamol UNIFLASH (125 MG/1.25 ML)

Acute Pain

India
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

A Study to Investigate the Receptor Occupancy of SK-1405 in Healthy, Caucasian, Male Subjects

Pruritus

United Kingdom

Search clinical trials for: SY-1425 (tamibarotene)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations